Keros Therapeutics (KROS) PT Raised to $27 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Price: $10.83 --0%
Rating Summary:
8 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
8 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Andreas Argyrides raised the price target on Keros Therapeutics (NASDAQ: KROS) to $27.00 (from $23.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
- Freshworks Inc (FRSH) PT Raised to $17 at UBS
- Sportradar Group AG (SRAD) PT Raised to $16 at StoneX
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
